Mediterranean diets and metabolic syndrome status in the PREDIMED randomized trial

Nancy Babio BSc PhD, Estefanía Toledo MD PhD, Ramón Estruch MD PhD, Emilio Ros MD PhD, Miguel A. Martínez-González MD PhD, Olga Castañer MD PhD, Mònica Bulló BSc PhD, Dolores Corella DPharm PhD, Fernando Arós MD PhD, Enrique Gómez-Gracia MD PhD, Valentina Ruiz-Gutiérrez PhD, Miquel Fiol MD PhD, Josep Basora MD, José V. Sorlí MD PhD, Jordi Salas-Salvadó MD PhD; for the PREDIMED Study Investigators*

Abstract

Background: Little evidence exists on the effect of an energy-unrestricted healthy diet on metabolic syndrome. We evaluated the long-term effect of Mediterranean diets ad libitum on the incidence or reversion of metabolic syndrome.

Methods: We performed a secondary analysis of the PREDIMED trial — a multicentre, randomized trial done between October 2003 and December 2010 that involved men and women (age 55–80 yr) at high risk for cardiovascular disease. Participants were randomly assigned to 1 of 3 dietary interventions: a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with nuts or advice on following a low-fat diet (the control group). The interventions did not include increased physical activity or weight loss as a goal. We analyzed available data from 5801 participants. We determined the effect of diet on incidence and reversion of metabolic syndrome using Cox regression analysis to calculate hazard ratios (HRs) and 95% confidence intervals (CIs).

Results: Over 4.8 years of follow-up, metabolic syndrome developed in 960 (50.0%) of the 1919 participants who did not have the condition at baseline. The risk of developing metabolic syndrome did not differ between participants assigned to the control diet and those assigned to either of the Mediterranean diets (control v. olive oil HR 1.10, 95% CI 0.94–1.30, p = 0.231; control v. nuts HR 1.08, 95% CI 0.92–1.27, p = 0.3). Reversion occurred in 958 (28.2%) of the 3392 participants who had metabolic syndrome at baseline. Compared with the control group, participants on either Mediterranean diet were more likely to undergo reversion (control v. olive oil HR 1.35, 95% CI 1.15–1.58, p < 0.001; control v. nuts HR 1.28, 95% CI 1.08–1.51, p < 0.001). Participants in the group receiving olive oil supplementation showed significant decreases in both central obesity and high fasting glucose (p = 0.02); participants in the group supplemented with nuts showed a significant decrease in central obesity.

Interpretation: A Mediterranean diet supplemented with either extra virgin olive oil or nuts is not associated with the onset of metabolic syndrome, but such diets are more likely to cause reversion of the condition. An energy-unrestricted Mediterranean diet may be useful in reducing the risks of central obesity and hyperglycemia in people at high risk of cardiovascular disease. Trial registration: ClinicalTrials.gov, no. ISRCTN35739639.

Mediterranean diet may be useful in reducing the risks of central obesity and hyperglycemia in people at high risk of cardiovascular disease.
The Mediterranean diet is recognized as one of the healthiest dietary patterns. It has shown benefits in patients with cardiovascular disease and in the prevention and treatment of related conditions, such as diabetes, hypertension and metabolic syndrome.

Several cross-sectional and prospective epidemiologic studies have suggested an inverse association between adherence to the Mediterranean diet and the prevalence or incidence of metabolic syndrome. Evidence from clinical trials has shown that an energy-restricted Mediterranean diet or adopting a Mediterranean diet after weight loss has a beneficial effect on metabolic syndrome. However, these studies did not determine whether the effect could be attributed to the weight loss or to the diets themselves.

Seminal data from the PREDIMED (PREvenção con DIeta MEDiterránea) study suggested that adherence to a Mediterranean diet supplemented with nuts reversed metabolic syndrome more so than advice to follow a low-fat diet. However, the report was based on data from only 1224 participants followed for 1 year. We have analyzed the data from the final PREDIMED cohort after a median follow-up of 4.8 years to determine the long-term effects of a Mediterranean diet on metabolic syndrome.

Methods

Study design and population

The PREDIMED study was a large, parallel-group, multicentre, randomized, controlled field trial designed to assess the effects of the Mediterranean diet on the primary prevention of cardiovascular disease (www.predimed.es).

The protocol, design and methods of the trial have been described elsewhere. Briefly, community-dwelling men (aged 55–80 yr) and women (aged 60–80 yr) with no previously documented cardiovascular disease were recruited for the study and were eligible to participate if they had either type 2 diabetes or at least 3 cardiovascular risk factors: hypertension, high plasma low-density lipoprotein (LDL) cholesterol, low plasma HDL cholesterol, overweight or obesity, current history of smoking and family history of premature coronary artery disease. From October 2003 to June 2009, 7447 participants were randomly assigned to 1 of 3 nutrition interventions (1:1:1). Two groups were advised to follow a Mediterranean diet supplemented with either extra-virgin olive oil (n = 2543) or nuts (n = 2454), and 1 group (the control group) was advised to follow a low-fat diet (n = 2450). The institutional review board of the hospital clinic in Barcelona, Spain, accredited by the United States Department of Health and Human Services Update for Federal Wide Assurance for the Protection of Human Subjects for International (non-US) Institutions approved the study protocol on July 16, 2002. The institutional review boards of the individual recruitment centres also approved the study protocol, and participants gave their informed consent.

To evaluate the effect of the dietary interventions on metabolic syndrome status, we analyzed data from those participants for whom biochemical determinations were available at baseline and for at least 2 years of follow-up. We performed two separate analyses: the first on the incidence of metabolic syndrome in participants who did not have the condition at baseline, and the second on reversion of metabolic syndrome in participants who had the condition at baseline.

Interventions

Personalized advice was given to participants in both Mediterranean diet groups to increase their adherence to the intervention. Participants in both Mediterranean diet groups received either extra-virgin olive oil (about 1 L/wk) or mixed nuts (30 g/d; 15 g walnuts, 7.5 g hazelnuts and 7.5 g almonds) at no cost; participants in the control group received small nonfood gifts. The nutrient composition of the olive oil and nuts used in the study was assessed. Participants were not advised on calorie restriction, and physical activity was not promoted for any intervention group.

At baseline and quarterly thereafter, dietitians gave individual and group training sessions to provide information on typical Mediterranean foods, seasonal shopping lists, meal plans and recipes. Participants assigned to the control diet received recommendations to reduce their intake of all types of fat, from both animal and vegetable sources. Before October 2006, participants in the control group had only received a leaflet describing the low-fat diet. Thereafter, they received personalized advice and were invited to group sessions held with the same frequency as in the Mediterranean groups. During each training session, participants in the Mediterranean diet groups completed a 14-item questionnaire to assess adherence to the intervention; participants in the control group completed a 9-item dietary screener to assess compliance with the low-fat diet.

Outcomes

Our primary outcome was metabolic syndrome status, which was defined in the PREDIMED study in accordance to the updated harmonized International Diabetes Federation and the Americ-
can Heart Association/National Heart, Lung, and Blood Institute criteria. We calculated the proportion of participants who did not meet criteria at baseline, but who had at least 3 components of metabolic syndrome yearly thereafter (i.e., incident metabolic syndrome). In addition, we calculated the proportion of participants who met criteria at baseline, but who had fewer than 3 components yearly thereafter (i.e., reversion of metabolic syndrome). We considered only the first change in status (incidence or reversion) in our analyses.

Measurements
At baseline and yearly for a median follow-up of 4.8 years, all of the participants were given personal interviews during which they completed the following items: a questionnaire about lifestyle variables, medical history and medication use; a 14-item validated questionnaire designed to assess adherence to the Mediterranean diet; a validated 137-item semi-quantitative food-frequency questionnaire and the validated Spanish version of the Minnesota leisure-time physical activity questionnaire. In addition, trained staff determined anthropometric variables and blood pressure. Blood samples were collected from all participants after an overnight fast. We measured fasting plasma glucose, total cholesterol, HDL cholesterol and triglyceride concentrations at baseline and yearly during follow-up using standard methods. Laboratory staff were blinded to the intervention group.

### Table 1: Baseline characteristics of the study participants

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mediterranean diet + EVOO, n = 1982</th>
<th>Mediterranean diet + nuts, n = 1885</th>
<th>Low-fat diet (control), n = 1934</th>
<th>p value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr</td>
<td>67.1 (6.2)</td>
<td>66.7 (6.0)</td>
<td>67.3 (6.2)</td>
<td>0.04</td>
</tr>
<tr>
<td>Male sex</td>
<td>40.9 (811)</td>
<td>45.0 (849)</td>
<td>40.2 (777)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Smoking history</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Former smoker</td>
<td>23.6 (468)</td>
<td>26.5 (499)</td>
<td>23.7 (459)</td>
<td>0.08</td>
</tr>
<tr>
<td>Current smoker</td>
<td>13.8 (273)</td>
<td>14.4 (272)</td>
<td>14.1 (273)</td>
<td>0.8</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>30.0 (3.8)</td>
<td>29.8 (3.8)</td>
<td>30.3 (4.1)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Waist circumference, cm</td>
<td>100.4 (10.2)</td>
<td>100.0 (10.5)</td>
<td>100.8 (10.7)</td>
<td>0.08</td>
</tr>
<tr>
<td>Leisure time physical activity, METs/min per d</td>
<td>233 (236)</td>
<td>249 (244)</td>
<td>210 (243)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Mediterranean diet score (0–14)</td>
<td>8.8 (1.9)</td>
<td>8.8 (1.9)</td>
<td>8.4 (1.9)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td>48.0 (952)</td>
<td>45.1 (850)</td>
<td>47.8 (925)</td>
<td>0.1</td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>65.1 (1291)</td>
<td>61.8 (1165)</td>
<td>64.7 (1251)</td>
<td>0.07</td>
</tr>
<tr>
<td>Metabolic syndrome component‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central obesity</td>
<td>74.6 (1465)</td>
<td>69.6 (1305)</td>
<td>75.3 (1440)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Hypertriglyceridemia</td>
<td>34.5 (682)</td>
<td>32.7 (615)</td>
<td>32.8 (631)</td>
<td>0.4</td>
</tr>
<tr>
<td>Low HDL cholesterol</td>
<td>29.4 (579)</td>
<td>28.3 (531)</td>
<td>29.1 (560)</td>
<td>0.8</td>
</tr>
<tr>
<td>Hypertension</td>
<td>93.4 (1849)</td>
<td>94.0 (1771)</td>
<td>94.6 (1830)</td>
<td>0.3</td>
</tr>
<tr>
<td>High fasting plasma glucose</td>
<td>65.3 (1291)</td>
<td>64.2 (1203)</td>
<td>65.9 (1271)</td>
<td>0.6</td>
</tr>
<tr>
<td>Use of medications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antihypertensive agents</td>
<td>72.0 (1 428)</td>
<td>73.0 (1 376)</td>
<td>73.4 (1 420)</td>
<td>0.3</td>
</tr>
<tr>
<td>Statins</td>
<td>4.1 (81)</td>
<td>4.6 (86)</td>
<td>3.5 (68)</td>
<td>0.3</td>
</tr>
<tr>
<td>Insulin</td>
<td>41.5 (822)</td>
<td>38.4 (726)</td>
<td>39.7 (767)</td>
<td>0.2</td>
</tr>
<tr>
<td>Hypoglycaemic agents</td>
<td>7.3 (145)</td>
<td>6.0 (113)</td>
<td>7.5 (144)</td>
<td>0.1</td>
</tr>
<tr>
<td>Aspirin or antiplatelet drugs</td>
<td>30.2 (598)</td>
<td>26.9 (505)</td>
<td>30.7 (593)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

Note: BMI = body mass index, EVOO = extra virgin olive oil, HDL = high-density lipoprotein, MET = metabolic equivalent of task.

†Unless otherwise stated.

‡Values determined using test for categorical variables and analysis of variance for continuous variables.

†Defined in accordance with the International Diabetes Federation and the American Heart Association/National Heart, Lung and Blood Institute criteria.
Statistical analyses
Assuming an expected incidence of metabolic syndrome of 21% and a hazard ratio (HR) of 0.7 for the comparison of the intervention groups with the control group, the statistical power for our analyses is 83%. Assuming an expected reversion rate of metabolic syndrome of 7.5% and a HR of 1.7 for the comparison of the intervention groups with the control group, the statistical power for our analyses is 92%.

We used the Bonferroni method to test multiple comparisons of the 5 components of metabolic syndrome between intervention groups at the end of follow-up. We used generalized estimating equations to assess changes in the incidence of metabolic syndrome between intervention groups during follow-up. We fitted Cox regression models to determine HRs and 95% confidence intervals (CIs) for incidence or reversion by intervention group.

For our primary analyses of incidence or reversion, the time variable was the interval between randomization and either the date of incidence or reversion, the date of the last follow-up visit, the date of death or the date on which the participant was lost to follow-up, whichever occurred first.

All p values are 2-tailed with a significance level of less than 0.05. We performed statistical analyses using SPSS version 19.0 and STATA version 12.0.

Results
Of the 7447 participants in the PREDIMED trial, biochemical determinations were available for 5801 (77.9%) (Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.140764/-/DC1). We found no differences in the main characteristics of participants between the total cohort of participants and those included in our analysis (data not shown).

Among participants with or without metabolic syndrome at baseline (Appendices 2 and 3, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.140764/-/DC1), the median Mediterranean diet score (as determined using the 14-item questionnaire) throughout follow-up was significantly higher among participants allocated to the Mediterranean diet groups compared with those in the control group.

Throughout follow-up, consumption of nuts and extra-virgin olive oil were significantly higher among participants allocated to the Mediterranean diets supplemented with nuts or olive oil, respec-

<table>
<thead>
<tr>
<th>Condition</th>
<th>Intervention, % (no.)</th>
<th>p value*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mediterranean diet + EVOO</td>
<td>Mediterranean diet + nuts</td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>n = 1982</td>
<td>n = 1885</td>
</tr>
<tr>
<td>At baseline</td>
<td>65.1 (1291)</td>
<td>61.8 (1165)</td>
</tr>
<tr>
<td>At final follow-up</td>
<td>66.6 (1320)</td>
<td>64.9 (1223)</td>
</tr>
<tr>
<td>Central obesity</td>
<td>n = 1981</td>
<td>n = 1897</td>
</tr>
<tr>
<td>At baseline</td>
<td>74.4 (1474)</td>
<td>69.5 (1319)</td>
</tr>
<tr>
<td>At final follow-up</td>
<td>74.1 (1467)</td>
<td>70.9 (1345)</td>
</tr>
<tr>
<td>Hypertriglyceridemia</td>
<td>n = 1994</td>
<td>n = 1891</td>
</tr>
<tr>
<td>At baseline</td>
<td>34.3 (683)</td>
<td>32.5 (615)</td>
</tr>
<tr>
<td>At final follow-up</td>
<td>32.6 (656)</td>
<td>30.6 (575)</td>
</tr>
<tr>
<td>Low HDL cholesterol</td>
<td>n = 1985</td>
<td>n = 1886</td>
</tr>
<tr>
<td>At baseline</td>
<td>29.3 (582)</td>
<td>28.2 (532)</td>
</tr>
<tr>
<td>At final follow-up</td>
<td>35.0 (694)</td>
<td>34.8 (656)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>n = 2032</td>
<td>n = 1934</td>
</tr>
<tr>
<td>At baseline</td>
<td>93.5 (1899)</td>
<td>93.8 (1814)</td>
</tr>
<tr>
<td>At final follow-up</td>
<td>95.4 (1938)</td>
<td>94.8 (1833)</td>
</tr>
<tr>
<td>High fasting plasma glucose</td>
<td>n = 2010</td>
<td>n = 1896</td>
</tr>
<tr>
<td>At baseline</td>
<td>65.6 (1319)</td>
<td>64.5 (1223)</td>
</tr>
<tr>
<td>At final follow-up</td>
<td>68.9 (1385)</td>
<td>68.4 (1296)</td>
</tr>
</tbody>
</table>

Note: EVOO = extra-virgin olive oil, HDL = high-density lipoprotein.
*p* test.
Changes in body weight and physical activity were small and did not differ significantly between groups (Appendix 5).

Of the 5801 participants included in our analysis (Table 1), 63.9% \( (n = 3707) \) met the criteria for metabolic syndrome at baseline. The prevalence of central obesity and high fasting plasma glucose were significantly higher in the control group at the end of follow-up (Table 2) than in the Mediterranean diet groups. We saw a significant difference in central obesity between Mediterranean diet groups at the end of follow-up (Bonferroni adjusted \( p = 0.025 \)). After a median follow-up of 4.8 years, we found a significantly smaller increase in the prevalence of metabolic syndrome among participants assigned to the Mediterranean diet supplemented with extra-virgin olive oil than among participants in the control group (\( p = 0.013 \)) (Figure 1).

We assessed incidence of metabolic syndrome for 2094 participants who did not have the condition at baseline (691 in the olive oil supplementation group, 720 in the nut supplementation group and 683 in the control group). Data were missing for some of the covariables needed to assess incidence for 175 participants. Thus, our analysis on incidence included data from 1919 participants.

Over a median follow-up of 3.2 yr (maximum 7 yr), we found no between-group differences in the cumulative incidence of metabolic syndrome or its components (Appendix 7). The risk of metabolic syndrome incidence (Table 3) did not differ significantly between the Mediterranean diet groups and the control group (control v. olive oil HR 1.10, 95% CI 0.94–1.30, \( p = 0.231 \); control v. nuts HR 1.08, 95% CI 0.92–1.27, \( p = 0.322 \)). In addition, the risk of each component of metabolic syndrome did not show significant between-group differences (Appendix 8).

To assess reversion, we included only those participants who had metabolic syndrome at baseline (\( n = 3707 \)); however, data were missing for 315 participants. Thus, we included data from 3392 participants in our analyses. During a median follow-up of 4.8 years, reversion occurred in 958 (28.2%) participants (Appendix 9). Compared with the control diet, both Mediterranean diets were significantly more likely to revert metabolic syndrome (control v. olive oil HR 1.35, 95% CI 1.15–1.58, \( p < 0.001 \); control v. nuts HR 1.37, 95% CI 1.16–1.60, \( p = 0.001 \)).

Figure 1: Prevalence of metabolic syndrome during follow-up. Error bars denote 95% confidence intervals. The changes were assessed with generalized estimating equations, and the \( p \) values shown are for the overall trend. Note: EVOO = extra-virgin olive oil.
1.28, 95% CI 1.08–1.51, \( p < 0.001 \)). The cumulative reversion rates for metabolic syndrome, central obesity and high fasting plasma glucose differed significantly among the 3 groups. Reversion was higher in both Mediterranean diet groups compared with the control group (Table 3, Appendix 10, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.140764/-/DC1).

Participants assigned to the Mediterranean diets were significantly more likely to no longer meet the criterion of central obesity compared with those in the control group (both \( p < 0.001 \)), even after adjustment for confounders (Appendix 11, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.140764/-/DC1). Compared with the control group, only the participants in the group supplemented with extra-virgin olive oil were more likely to no longer meet the criterion of high fasting plasma glucose (\( p = 0.02 \)).

Discussion

In this large, multicentre, randomized controlled trial involving people with high cardiovascular risk, a Mediterranean diet supplemented with extra-virgin olive oil was associated with a smaller increase in the prevalence of metabolic syndrome compared with advice on following a low-fat diet. However, we found no beneficial effect of a Mediterranean diet on incidence of new-onset metabolic syndrome. Thus, the smaller increase in prevalence was likely due to reversion. Because there were no between-group differences in weight loss or energy expenditure, the change is likely attributable to the difference in dietary patterns.

Our results are not consistent with those of observational studies\(^24\) that have shown a beneficial effect of a Mediterranean diet on the incidence of metabolic syndrome. However, our results are consistent with those of Esposito and colleagues\(^33\), who found beneficial effects on metabolic syndrome and its components with an energy-restricted Mediterranean diet in a short clinical trial. Contrary to our study, their results could have been due to energy restriction leading to substantial weight loss.\(^33\)

Similar to the previous PREDIMED report\(^35\), we found a beneficial effect of a Mediterranean diet on reversion of metabolic syndrome, but not on the incidence of the condition. However, we did see a net beneficial effect on prevalence as a result of reversion.

We found the Mediterranean diet supplemented with extra-virgin olive oil to have the most beneficial effect on central obesity and hyperglycemia. These results concur with those of cross-sectional\(^26,41,42\) and prospective epidemiologic studies\(^24,30,32\) that showed an inverse association between adherence to a Mediterranean diet and central obesity.

We can speculate that a Mediterranean diet, particularly one supplemented with extra-virgin olive oil (which has anti-inflammatory properties), could exert positive effects on fat redistribution. In a short-term experimental crossover study involving participants with obesity and insulin resistance, an isocaloric Mediterranean diet rich in extra-virgin olive oil prevented accumulation of central body fat compared with a low-fat diet, without affecting body weight.\(^43\) In addition, there is evidence that patients with type 2 diabetes involved in weight maintenance programs tend to have a disproportionate loss of lower body versus upper body fat compared with patients given a diet rich in monounsaturated fatty acids.\(^44\)

The protective effect on the hyperglycemia component of the metabolic syndrome that we saw with olive oil supplementation is also consistent with the efficacy of dietary monounsatu-

<table>
<thead>
<tr>
<th>Model</th>
<th>Incidence HR (95% CI)†</th>
<th>Reversion HR (95% CI)†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mediterranean diet + EVOO v. control</td>
<td>Mediterranean diet + nuts v. control</td>
</tr>
<tr>
<td>Crude model</td>
<td>1.04 (0.89–1.21)</td>
<td>1.04 (0.88–1.19)</td>
</tr>
<tr>
<td>Age-, sex- and centre-adjusted model</td>
<td>1.03 (0.88–1.21)</td>
<td>1.01 (0.86–1.19)</td>
</tr>
<tr>
<td>Multivariable adjusted model†</td>
<td>1.10 (0.94–1.30)</td>
<td>1.08 (0.92–1.27)</td>
</tr>
</tbody>
</table>

Note: CI = confidence interval, EVOO = extra-virgin olive oil, HR = hazard ratio.
*Defined in accordance with the International Diabetes Federation and the American Heart Association/National Heart, Lung, and Blood Institute criteria.\(^38\)
†Cox regression model.
‡Adjusted for sex, age, Mediterranean diet score, energy intake, body mass index, physical activity, smoking and antidiabetic drugs other than insulin. All models were stratified by recruitment centre.
rated fatty acids for reducing cardiovascular risk factors related to metabolic syndrome\textsuperscript{45} and the risk of insulin resistance and diabetes.\textsuperscript{21} Several controlled interventions have shown that diets rich in monounsaturated fatty acids improve insulin sensitivity compared with those high in saturated fatty acids.\textsuperscript{43,46}

The Mediterranean diet includes components beyond monounsaturated fatty acids that have been reported to improve inflammation, oxidative stress, insulin resistance and secretion — pathogenic factors in obesity, diabetes and metabolic syndrome. For example, many fruits, vegetables and seeds contain minerals, polyphenols and other phytochemicals that combat oxidative stress, inflammation and insulin resistance.\textsuperscript{37,44} Extra-virgin olive oil and nuts show potent anti-inflammatory\textsuperscript{49} and antioxidant effects, and both of the PREDIMED Mediterranean diets have shown these effects.\textsuperscript{50,51} Many components of the Mediterranean diet are likely to be beneficial in terms of glucose metabolism, reducing the risk of diabetes.\textsuperscript{21} However, the recognized protective effect of the Mediterranean diet was not enough to prevent metabolic syndrome in our study population.

**Limitations**

Incidence and reversion of metabolic syndrome were secondary end-points of the PREDIMED trial, making our analyses exploratory in nature. Because our sample comprised older participants at high risk of cardiovascular disease, our results cannot be generalized to the general population. Complete data were not available for analysis of some of the participants; we had greater losses during follow-up in the control group, but participants who dropped out had a worse cardiovascular risk profile at baseline than participants who remained in the study, suggesting a bias toward benefit in the control group.

**Conclusion**

Mediterranean diets supplemented with olive oil or nuts were not associated with a reduced incidence of metabolic syndrome compared with a low-fat diet; however, both diets were associated with a significant rate of reversion of metabolic syndrome. Such diets may be useful in reducing central obesity and hyperglycemia in patients with high risk of cardiovascular disease.

**References**


Competing interests: Ramón Estruch serves on the board of and has received lecture fees from the Research Foundation on Wine and Nutrition (FIVIN); he serves on the boards of the Beer and Health Foundation and the European Foundation for Alcohol Research; he has received lecture fees from Cervexeres de España and Sanofi-Aventis and grant support from Novartis. Emilio Ros serves on the board of and has received travel and grant support from the California Walnut Commission; he serves on the board of the Flora Foundation (Unilever); he serves on the board of and has received lecture fees from Roche; he serves on the board of and has received grant support from Amgen; he has received consulting fees from Damm and Abbott Laboratories; he has received con- sulting fees, lecture fees and grant support from Merck; he has received lecture fees from Danone, Pace, Astra Zeneca and Rottapharm; he has received lecture fees, grant support and payment for the development of educational presenta- tions from Ferrer; he has received payment for the development of educational presentations from Recordati; and he has received grant support from Sanofi-Aventis, Takeda, Daiichi Sankyo, Nutrexa, Feiraco, Unilever, and Karo Bio. Fer- nando Arós has received payment for the development of educational presentations from Menarini and Astra Zeneca. Rosa Lamuela-Raventos serves on the board of and has received lecture fees from FIVIN; has received lecture fees from Cervexeres de España; and has received lecture fees and travel support from PepsiCo. Lluís Serra-Majem serves on the boards of the Mediterranean Diet Foundation and the Beer and Health Foundation; he is a member of the scientific advisory board and has received consulting fees and grant support from the European Hyration Institute; he has received lecture fees from the International Nut Council; he has received travel support for conferences from Nestlé. Xavier Pintó serves on the board of and has received grant support from the Residual Risk Reduction Initiative Foundation; he serves on the board of Omegafor; he serves on the board of and has received payment for the development of educational presentations and grant support from Ferrer; he has received consulting fees from Abbott Laboratories; he has received lecture fees and grant support from Merck and Roche; he has received travel and fees from Danone and Esteve; he has received payment for the development of educational presentations from Menarini; and he has received grant sup- port from Sanofi-Aventis, Kowa, Unilever, Boehringer Ingel- heim and Karo Bio. Jordi Salas-Salvadó serves on the board of and has received grant support from the International Nut and Dried Fruit Council; he has received consulting fees from Danone; and he has received grant support from Eroski and Nestlé. No other competing interests were declared.

Afililaciones: Human Nutrition Unit (Babio, Bulló, Basora, Salas-Salvadó), Faculty of Medicine and Health Sciences, Biochemistry Biotechnology Department, Universitat Rovira i Virgili, and Hospital Universitari de Sant Joan de Reus, IISPV, Reus, Spain; Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERobn) (Babio, Toledo, Estruch, Martínez-González, Arós, Gómez-Gracia, Ruiz-Gutiérrez, Fiol, Lapetra, Corella, Babio, Toledo, Estruch, Castañer, Bulló, Corella, Gómez-Gracia, Ruiz-Gutiérrez, Fiol, Lapetra, Lamuela-Raventos, Serra-Majem, Pintó, Basora, Sorlí, Salas-Salvadó), Institute of Health Carlos III, Madrid, Spain; Department of Preventive Medicine and Public Health (Toledo, Martínez-González), University of Navarra, Pam- plona, Spain; Department of Internal Medicine (Estruch), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barce- lona, Spain; Lipid Clinic (Ros), Endocrinology and Nutrition Service, IDIBAPS, Hospital Clinic, University of Barcelona, Barce- lona, Spain; Cardiovascular Risk and Nutrition
Research Group (Castañer), Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona Biomedical Research Park, Barcelona, Spain; Department of Preventive Medicine (Corella, Sorli), University of Valencia, Valencia, Spain; Department of Cardiology (Arós), University Hospital Txagorritxu, Vitoria, Spain; Department of Preventive Medicine (Gómez-Gracia), University of Malaga, Malaga, Spain; Instituto de la Grasa (Ruiz-Gutiérrez), Consejo Superior de Investigaciones Científicas, Seville; Instituto de Investigación Sanitaria de Palma (Fiol), Hospital Universitario Son Espases, Mallorca; Department of Family Medicine (Lapetra), Primary Care Division of Seville, San Pablo Health Center, Seville; Department of Nutrition and Food Science (Lamuela-Raventos), School of Pharmacy, Xarxa de Referència en Tecnología dels Aliments, Instituto de Investigación en Nutrición y Seguridad Alimentaria, University of Barcelona, Barcelona, Spain; Department of Clinical Sciences (Serra-Majem), University of Las Palmas de Gran Canaria, Las Palmas, Spain; Lipids and Vascular Risk Unit (Pintó), Internal Medicine, Hospital Universitario de Bellvitge, Hospital de Llobregat, Barcelona, Spain; Primary Care Division (Basora), Catalan Institute of Health, Institut Universitari d’Investigació en Atenció Primària Jordi Gol, Tarragona-Reus, Spain.

Contributors: Nancy Babio and Jordi Salas-Salvadó had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Emilio Ros, Miguel Martínez-González, Dolores Corella, Fernando Arós, Enrique Gómez-Gracia, Valentina Ruiz-Gutiérrez, Miquel Fiol, José Lapetra, Rosa M. Lamuela-Raventos, Lluís Serra-Majem, Xavier Pintó and Jordi Salas-Salvadó. Analysis and interpretation of data: Nancy Babio, Estefanía Toledo, Miguel Martínez-González and Jordi Salas-Salvadó. Drafting of the manuscript: Nancy Babio and Jordi Salas-Salvadó. Critical revision of the manuscript for important intellectual content: All the authors. Statistical analysis: Nancy Babio, Estefanía Toledo.

The PREDIMED Study Investigators: C. Viñas, R. Casas, J.M. Baena, M. Oller, J. Amat, I. Duaso, Y. García, C. Iglesias and J. Benavent (Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain); A. Sánchez-Tainta, E. Toledo, P. Buil-Cosiales, M. Serrano-Martínez, J. Díez-Espino, A. García-Arellano, I. Zazpe and J. Basterra-Gortari (University of Navarra, Primary Care Division Centres, Pamplona, Spain); R. González, C. Molina, M. Sorli, J. García-Roselló, J., Fernández-Ballart, A. Castro, R. Sagarrà, P. Pedret, F. Paris and M. Llauradó (University Rovira i Virgili, Reus, Spain); S. Tello, J. Vila, M. Fito and H. Schröder (Institute of Recerca Hospital del Mar, Barcelona, Spain); F. Aros del Hierro and J. Algorta (University Hospital of Alava, Vitoria, Spain); R. Benítez Pont, M. Bianchi Alba, J., Fernández-Crehuet Navajas and E. Gómez-Gracia (University of Málaga, Málaga, Spain); F.J. García, P. Roman, J.M. Santos and J. Lapetra (Department of Family Medicine, Primary Care Division of Sevilla, Seville, Spain); J. Álvarez-Pérez, E. Díez Benítez, I. Baustista Castaño and A. Sánchez-Villegas (University of Las Palmas de Gran Canaria, Las Palmas, Spain).

Funding: CIBERobn is an initiative of ISCIII, Spain. Supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140, to Ramón Estruch; RTIC RD 06/0045, to Miguel Martínez-González and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición [CIBERobn]), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04–2239, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI07/0473, P110/01407, P110/02658, P111/01647, and P11/02505; PI13/00462, Ministerio de Ciencia e Innovación (AGL-2009–13906-C02 and AGL2010–22319-C03), Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI1015/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVACOMP2010–181, GVACOMP2011–151, CS2010–AP–111, and CS2011–AP–042), and Regional Government of Navarra (P27/2011). None of the funding sources played a role in the design, collection, analysis or interpretation of the data or in the decision to submit the manuscript for publication.

Data sharing: The PREDIMED trial data are not available for sharing.

Acknowledgements: The authors thank the participants for their enthusiastic collaboration, the PREDIMED personnel for their excellent assistance and the personnel of all affiliated primary care centres.